Results 11 to 20 of about 743,371 (240)
The emerging role of BET inhibitors in breast cancer [PDF]
Breast, 2020 Bromodomain and extraterminal domain (BET) proteins are epigenetic molecules that regulate the expression of multiple genes involved in carcinogenesis.
Angeliki Andrikopoulou +4 more
doaj +6 more sources
A Minireview on BET Inhibitors: Beyond Bromodomain Targeting [PDF]
BiomedicinesBromodomain and extra-terminal domain (BET) proteins are epigenetic readers that recognize the histone acetylation code and play a critical role in regulating gene transcription.
Mikhail S. Iudin +4 more
doaj +5 more sources
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
Molecules, 2023 The mammalian bromodomain and extra-terminal domain (BET) family of proteins consists of four conserved members (Brd2, Brd3, Brd4, and Brdt) that regulate numerous cancer-related and immunity-associated genes.
Kenneth K. W. To +3 more
doaj +4 more sources
Advanced Science, 2023 The development of castration‐resistant prostate cancer (CRPC) is a significant factor that reduces life expectancy among patients with prostate cancer.
Huaiyuan Liang +7 more
doaj +2 more sources
Identification of BET inhibitors (BETi) against solitary fibrous tumor (SFT) through high-throughput screening (HTS) [PDF]
Neoplasia: An International Journal for Oncology ResearchCancers, especially fusion oncoprotein (FO)-driven hematological cancers and sarcomas, often develop from a low number of key mutations. Solitary Fibrous Tumor (SFT) is a rare mesenchymal tumor driven by the NAB2-STAT6 oncofusion gene.
Jose L. Mondaza-Hernandez +11 more
doaj +2 more sources
RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma [PDF]
Scientific ReportsBromodomain and extra-terminal domain (BET) proteins are therapeutic targets in several cancers including the most common malignant adult brain tumor glioblastoma (GBM). Multiple small molecule inhibitors of BET proteins have been utilized in preclinical
Anna M. Jermakowicz +11 more
doaj +2 more sources
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma [PDF]
eJHaem, 2022 Inhibitors of the Bromo‐ and Extra‐Terminal domain (BET) family proteins have strong preclinical antitumor activity in multiple tumor models, including lymphomas. Limited single‐agent activity has been reported in the clinical setting.
Filippo Spriano +14 more
doaj +2 more sources
, 2019 9th Bet Debora Conference "Jewish Women: Being Present, Bringing Change" covered following topics: contemporary women’s perspectives on Jewish tradition; advocacy for other minority groups: activism against antisemitism, antiziganism, racism, and ...
core +7 more sources
Role of BET Inhibitors in Triple Negative Breast Cancers. [PDF]
Cancers (Basel), 2020 Bromodomain and extraterminal domain (BET) proteins have evolved as key multifunctional super-regulators that control gene expression. These proteins have been shown to upregulate transcriptional machinery leading to over expression of genes involved in ...
Khandekar D, Tiriveedhi V.
europepmc +4 more sources
Frontiers in Pharmacology, 2021 Background: The upregulated expression of BET proteins is closely associated with the occurrence and development of hematological malignancies and solid tumors.
Yanli Sun +7 more
doaj +1 more source